Vertex Pharmaceuticals Incorporated
VRTX
$552.99
$5.400.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.24% | 8.21% | 9.55% | 10.99% | 11.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.45% | 7.82% | 9.55% | 10.99% | 12.06% |
| Cost of Revenue | 7.01% | 0.87% | 1.24% | 9.78% | 3.54% |
| Gross Profit | 17.23% | 14.36% | 17.48% | 12.01% | 20.79% |
| SG&A Expenses | 37.12% | 24.55% | 28.97% | 19.71% | 14.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.07% | 6.27% | 7.06% | 12.03% | 5.83% |
| Operating Income | 9.92% | 10.45% | 13.58% | 9.47% | 23.46% |
| Income Before Tax | 8.48% | 71.54% | 17.11% | 6.10% | 137.83% |
| Income Tax Expenses | 16.75% | 163.38% | -37.40% | 20.82% | 23.57% |
| Earnings from Continuing Operations | 6.48% | 59.59% | 30.46% | 3.59% | 128.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.48% | 59.59% | 30.46% | 3.59% | 128.74% |
| EBIT | 9.92% | 10.45% | 13.58% | 9.47% | 23.46% |
| EBITDA | 9.89% | 10.67% | 13.60% | 9.12% | 21.94% |
| EPS Basic | 7.73% | 61.34% | 32.31% | 4.56% | 128.90% |
| Normalized Basic EPS | 12.44% | 10.22% | 14.84% | 10.43% | 20.13% |
| EPS Diluted | 8.02% | 61.45% | 32.87% | 4.74% | 128.66% |
| Normalized Diluted EPS | 12.74% | 10.38% | 15.18% | 10.85% | 19.11% |
| Average Basic Shares Outstanding | -1.17% | -1.09% | -1.40% | -0.93% | -0.54% |
| Average Diluted Shares Outstanding | -1.43% | -1.23% | -1.69% | -1.30% | 0.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |